Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1).
暂无分享，去创建一个
E. Hollander | N. Fineberg | J. Grant | D. Baldwin | K. Laws | L. Drummond | S. Chamberlain | J. Reid | D. Wellsted | L. Pellegrini | V. Nezgovorova
[1] Anu Asnaani,et al. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial. , 2022, JAMA psychiatry.
[2] D. Baldwin,et al. Patient experience of lasting negative effects of psychological interventions for anxiety and depression in secondary mental health care services: a national cross-sectional study , 2021, BMC Psychiatry.
[3] Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials , 2017, British Medical Journal.
[4] E. Hollander,et al. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. , 2010, The Journal of clinical psychiatry.
[5] N. Fineberg,et al. Evidence-based pharmacotherapy of obsessive-compulsive disorder. , 2005, The international journal of neuropsychopharmacology.